Adjuvant Pembrolizumab in Resected Stage IIB or IIC Melanoma

Source: The Asco Post, March 2024

As reported in the Journal of Clinical Oncology by Jason J. Luke, MD, FACP, and colleagues, the final prespecified analysis of distant metastasis–free survival in the phase III KEYNOTE-716 trial showed continued benefit with adjuvant pembrolizumab vs placebo in patients with resected stage IIB or IIC melanoma.

The primary analysis of the trial supported the December 2021 approval of pembrolizumab in this setting, showing significant improvements in recurrence-free and distant metastasis–free survival.

Study Details
In the trial, 976 patients aged ? 12 years with newly diagnosed disease who had undergone resection were randomly assigned to receive adjuvant pembrolizumab at 200 mg or 2 mg/kg up to 200 mg in pediatric patients (n = 487) or placebo (n = 489) once every 3 weeks for 17 cycles or until disease recurrence or unacceptable toxicity.
READ THE ORIGINAL FULL ARTICLE